PathAI

PathAI reports FDA qualification of AIM-MASH AI Assist through the Drug Development Tool Biomarker Qualification Program for a defined context of use in MASH clinical trials. This regulatory trial-enablement milestone is distinct from AISight deployment evidence; the tool is not for diagnostic procedures.

PathAI AISight is deployed across major pathology networks and health systems, including nationwide Labcorp rollout, MedStar Health and international clinical deployments.

PathAI AISight is deployed across major pathology networks and health systems, including nationwide Labcorp rollout, MedStar Health and international clinical deployments.

PathAI reports a network of more than 450 board-certified pathologists and over 32.5 million annotations used for training and validation of its AI algorithms. This documents a specific expert-labelled data development capability beyond broad pathology algorithm coverage.

PathAI develops digital pathology infrastructure and AI algorithms for diagnostics, biomarker analysis and clinical trials.

PathAI develops digital pathology infrastructure and AI algorithms for diagnostics, biomarker analysis and clinical trials.

PathAI raised $165M in Series C financing led by D1 Capital and Kaiser Permanente with strategic investors including Bristol Myers Squibb, Labcorp and Merck; its platform now serves 90% of the top 15 biopharma companies and has expanded FDA-cleared AISight Dx into nationwide Labcorp deployment.

PathAI operates FDA-cleared and CE-IVD pathology platforms, broad biopharma collaborations and enterprise clinical deployments.

PathAI operates FDA-cleared and CE-IVD pathology platforms, broad biopharma collaborations and enterprise clinical deployments.

PathAI's November 2023 announcement states AISight renders DICOM Visible Light Whole Slide Microscopy images and supports enterprise image-architecture integration.

Computer vision and ML skills transfer broadly, but pathology, diagnostics and regulated clinical expertise materially constrain full portability.

Computer vision and ML skills transfer broadly, but pathology, diagnostics and regulated clinical expertise materially constrain full portability.